Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the company announced it has reached regulatory alignment on a path to accelerated approval with the FDA that will require it to run an additional study, removing the overhang on the stock for many investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $20 from $14 at RBC Capital
- Wells upgrades uniQure on ‘high likelihood of success’ in Huntington’s
- uniQure upgraded to Overweight from Equal Weight at Wells Fargo
- Oracle reports mixed Q2, Gen Digital to acquire MoneyLion: Morning Buzz
- uniQure upgraded to Strong Buy at Raymond James after FDA alignment reached